文献速递消化道肿瘤与早癌消化内镜

小RNA测序粪便microRNA特征可准确区分结直肠癌:多中心研究结果

A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study.
PubMed 文献 · Gastroenterology · 2023-05-30

该多中心横断面研究对1273份小RNA测序样本进行分析,在意大利和捷克队列(155例结直肠癌、87例腺瘤、96例其他肠道疾病、141例结肠镜阴性对照)中鉴定出25个粪便miRNA在结直肠癌患者中表达改变,并构建5-miRNA特征(miR-149-3p、miR-607-5p、miR-1246、miR-4488、miR-6777-5p)区分患者与对照(AUC 0.86,95%CI 0.79-0.94),在独立队列中验证(AUC 0.96,95%CI 0.92-1.00)。

要点

  • 5-miRNA粪便特征区分结直肠癌与对照的AUC为0.86(95%CI 0.79-0.94),独立验证AUC为0.96(95%CI 0.92-1.00)。
  • 该特征区分对照与低/高分期肿瘤及进展期腺瘤的AUC为0.82(95%CI 0.71-0.97)。
  • 粪便免疫化学检测残留样本的miRNA谱与防腐缓冲液采集粪便样本相关性良好。

核心结论

  • 全面的粪便miRNome分析鉴定出一个可准确区分结直肠癌的特征,旨在改善无创诊断和筛查策略。

研究设计与样本

  • 多中心横断面研究,共进行1273次小RNA测序实验,涉及多种生物样本。
  • 粪便样本来自意大利和捷克队列(155例结直肠癌、87例腺瘤、96例其他肠道疾病、141例结肠镜阴性对照),另在141例结直肠癌患者和80名健康志愿者的粪便样本中测试。
  • 同时比较了132例肿瘤/腺瘤及配对癌旁黏膜、210份血浆细胞外囊泡样本和185份粪便免疫化学检测残留样本的miRNA谱。

主要发现

  • 25个miRNA在两个队列的结直肠癌患者粪便中均显示表达水平改变(校正P < .05)。
  • 5-miRNA特征(miR-149-3p、miR-607-5p、miR-1246、miR-4488、miR-6777-5p)区分患者与对照的AUC为0.86(95%CI 0.79-0.94),在独立队列中验证AUC为0.96(95%CI 0.92-1.00)。
  • 该特征区分对照与低/高分期肿瘤及进展期腺瘤的AUC为0.82(95%CI 0.71-0.97)。
  • 组织miRNA谱与粪便样本一致,不同胃肠道疾病的粪便谱突出了结直肠癌特异性失调的miRNA。
  • 粪便免疫化学检测残留样本的miRNA谱与防腐缓冲液采集粪便样本相关性良好,其改变可在腺瘤或结直肠癌患者中检测到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fecal tests currently used for colorectal cancer (CRC) screening show limited accuracy in detecting early tumors or precancerous lesions. In this respect, we comprehensively evaluated stool microRNA (miRNA) profiles as biomarkers for noninvasive CRC diagnosis. METHODS: A total of 1273 small RNA sequencing experiments were performed in multiple biospecimens. In a cross-sectional study, miRNA profiles were investigated in fecal samples from an Italian and a Czech cohort (155 CRCs, 87 adenomas, 96 other intestinal diseases, 141 colonoscopy-negative controls). A predictive miRNA signature for cancer detection was defined by a machine learning strategy and tested in additional fecal samples from 141 CRC patients and 80 healthy volunteers. miRNA profiles were compared with those of 132 tumors/adenomas paired with adjacent mucosa, 210 plasma extracellular vesicle samples, and 185 fecal immunochemical test leftover samples. RESULTS: Twenty-five miRNAs showed altered levels in the stool of CRC patients in both cohorts (adjusted P < .05). A 5-miRNA signature, including miR-149-3p, miR-607-5p, miR-1246, miR-4488, and miR-6777-5p, distinguished patients from control individuals (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.79-0.94) and was validated in an independent cohort (AUC, 0.96; 95% CI, 0.92-1.00). The signature classified control individuals from patients with low-/high-stage tumors and advanced adenomas (AUC, 0.82; 95% CI, 0.71-0.97). Tissue miRNA profiles mirrored those of stool samples, and fecal profiles of different gastrointestinal diseases highlighted miRNAs specifically dysregulated in CRC. miRNA profiles in fecal immunochemical test leftover samples showed good correlation with those of stool collected in preservative buffer, and their alterations could be detected in adenoma or CRC patients. CONCLUSIONS: Our comprehensive fecal miRNome analysis identified a signature accurately discriminating cancer aimed at improving noninvasive diagnosis and screening strategies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Pardini B, Ferrero G, Tarallo S, et al. A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study. Gastroenterology. 2023. PMID: 37263306. doi:10.1053/j.gastro.2023.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。